These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 17766663)

  • 1. Response to "Warning flags for erythropoiesis-stimulating agents and cancer-associated anemia".
    Littlewood TJ
    Oncologist; 2007 Aug; 12(8):1031-2; author reply 1032-4. PubMed ID: 17766663
    [No Abstract]   [Full Text] [Related]  

  • 2. Warning flags for erythropoiesis-stimulating agents and cancer-associated anemia.
    Lappin TR; Maxwell AP; Johnston PG
    Oncologist; 2007 Apr; 12(4):362-5. PubMed ID: 17470677
    [No Abstract]   [Full Text] [Related]  

  • 3. Response to "effect of patient exclusion criteria on the efficacy of erythropoiesis-stimulating agents in patients with cancer-related anemia".
    Coiffier B
    Oncologist; 2005 Oct; 10(9):762-3; author reply 764-5. PubMed ID: 16249359
    [No Abstract]   [Full Text] [Related]  

  • 4. Erythropoiesis-stimulating agents in patients with cancer: update on safety issues.
    Pirker R
    Expert Opin Drug Saf; 2009 Sep; 8(5):515-22. PubMed ID: 19637988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythropoiesis-Stimulating Agents and Cancer: Myth or Truth.
    Choi MJ; Yee J
    Adv Chronic Kidney Dis; 2019 Jul; 26(4):221-224. PubMed ID: 31477251
    [No Abstract]   [Full Text] [Related]  

  • 6. Weighing the hazards of erythropoiesis stimulation in patients with cancer.
    Khuri FR
    N Engl J Med; 2007 Jun; 356(24):2445-8. PubMed ID: 17568023
    [No Abstract]   [Full Text] [Related]  

  • 7. Tips for erythropoiesis-stimulating agent treatment of renal anemia.
    Tomosugi N; Koshino Y
    Clin Exp Nephrol; 2020 Jan; 24(1):105-106. PubMed ID: 31617026
    [No Abstract]   [Full Text] [Related]  

  • 8. Is it safe to use erythropoiesis-stimulating agents to treat anemia in chronic kidney disease patients with active malignancies?
    Gupta G; Choi MJ
    Semin Dial; 2011; 24(4):379-81. PubMed ID: 21801225
    [No Abstract]   [Full Text] [Related]  

  • 9. Erythropoietins in oncology.
    Lattanzi SC
    N Engl J Med; 2007 Sep; 357(12):1262; author reply 1262-3. PubMed ID: 17881762
    [No Abstract]   [Full Text] [Related]  

  • 10. Anemia in cancer: update on studies of erythropoiesis-stimulating agents.
    Burstein HJ
    J Support Oncol; 2007 Apr; 5(4 Suppl 2):5-26. PubMed ID: 17550053
    [No Abstract]   [Full Text] [Related]  

  • 11. The role of the pharmacist in optimizing the use of erythropoietin stimulating agents.
    Gebara SN; Moubayed H
    J Oncol Pharm Pract; 2010 Mar; 16(1):33-7. PubMed ID: 19401308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythropoiesis-stimulating agents in gynecological malignancies: A study-level meta-analysis.
    Marchetti C; De Felice F; Palaia I; Musio D; Muzii L; Tombolini V; Benedetti Panici P
    Crit Rev Oncol Hematol; 2016 Mar; 99():123-8. PubMed ID: 26748593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erythropoiesis-stimulating agents in ovarian cancer patients receiving chemotherapy: to treat or not to treat?
    Marchetti C; Palaia I; Benedetti Panici P
    Int J Gynecol Cancer; 2013 Jun; 23(5):783-4. PubMed ID: 23694979
    [No Abstract]   [Full Text] [Related]  

  • 14. Reimbursement for erythropoiesis-stimulating agents poses challenges.
    Traynor K
    Am J Health Syst Pharm; 2008 Mar; 65(5):385-6. PubMed ID: 18281727
    [No Abstract]   [Full Text] [Related]  

  • 15. Erythropoiesis-stimulating agents in the treatment of cancer-associated anemia.
    Kara O; Dizdar O; Altundag K
    JAMA; 2008 Dec; 300(24):2855; author reply 2855-7. PubMed ID: 19109113
    [No Abstract]   [Full Text] [Related]  

  • 16. Treating anemia with erythropoiesis-stimulating agents: effects on quality of life.
    Moossavi S; Freedman BI
    Arch Intern Med; 2009 Jun; 169(12):1100-1. PubMed ID: 19546408
    [No Abstract]   [Full Text] [Related]  

  • 17. Erythropoiesis-stimulating agents (ESAs), from chemotherapy-induced anemia to any cancer-related anemia?
    Venturino A; Colloca G
    Ann Oncol; 2010 Apr; 21(4):905-906. PubMed ID: 20032124
    [No Abstract]   [Full Text] [Related]  

  • 18. Erythropoiesis-stimulating agents (ESAs): do they still have a role in chemotherapy-induced anemia (CIA)?
    Bormanis J; Quirt I; Chang J; Kouroukis CT; MacDonald D; Melosky B; Verma S; Couture F
    Crit Rev Oncol Hematol; 2013 Aug; 87(2):132-9. PubMed ID: 23357249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials.
    Bohlius J; Schmidlin K; Brillant C; Schwarzer G; Trelle S; Seidenfeld J; Zwahlen M; Clarke M; Weingart O; Kluge S; Piper M; Rades D; Steensma DP; Djulbegovic B; Fey MF; Ray-Coquard I; Machtay M; Moebus V; Thomas G; Untch M; Schumacher M; Egger M; Engert A
    Lancet; 2009 May; 373(9674):1532-42. PubMed ID: 19410717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triumph and tragedy: anemia management in chronic kidney disease.
    Novak JE; Szczech LA
    Curr Opin Nephrol Hypertens; 2008 Nov; 17(6):580-8. PubMed ID: 18941350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.